Anti-CD20 Therapy Safety and Outcomes in Pregnancy

Podcast: Weekly Neurology Deep Dive - A review of recent impactful publications in the field of Neurology · Amer Ghavanini

Opublikowano: 2026-08-30

Recent clinical reviews and real-world registry data indicate that anti-CD20 monoclonal antibodies are generally safe for women of reproductive age managing multiple sclerosis and other autoimmune conditions. Because these drugs do not significantly cross the placenta until the second trimester, exposure during the preconception period or early pregnancy does not appear to increase the risk of congenital malformations. While infants exposed later in gestation may experience transient B-cell depletion, they typically recover within six months without a heightened risk of serious infection. Research suggests that spontaneous abortion rates remain within the expected range for the general population, although some data show...